SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate as the token's massive price appreciation triggers accusations of a pump-and-dump scheme and market manipulation. While some traders celebrate the rapid gains fueled by short squeezes and upcoming event catalysts, others are issuing urgent warnings about concentrated supply ownership and the high risk of a significant correction.

"What's Updog?" is a Community Led token.

UpDog

UpDog is capturing attention with a highly active community leveraging viral wordplay and a dedicated social presence to drive engagement and project visibility. Supporters are actively encouraging ecosystem participation through consistent branding and interactive community-led initiatives.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining traction as a BlockDAG project specifically engineered to serve as an economic infrastructure for autonomous AI agents, with community members highlighting its potential for low-fee transactions and verifiable work utility. Discussions center on its positioning as an early-stage, high-risk micro-cap alternative within the growing AI-focused blockchain sector.

Daddy Darth Vader

The community is engaged in a speculative "Daddy War" between competing meme coins, debating potential pump-and-dump mechanics and liquidity strategies. Discussions are dominated by conflicting views on the developer's transparency and the volatility of these nano-cap assets.

What Is Request (REQ)? The Request (REQ) utility token, launched in 2017, ensures the performance and stability of the Request Network. The Request Network itself is an Ethereum-based decentralized payment system where anyone can request a payment and receive money through secure means. It removes the requirement for third parties in order to provide a cheaper, more secure payment solution that works with all global currencies.  When a user creates a request for payment, they define to which address the payment needs to be allocated and what the amount is. The user can also define the terms and conditions of the payment, upgrading a simple request into an invoice. Once this is completed, the user can share their request to be paid by their counterparty.  Every step is documented and stored on the Request network, allowing everyone involved to easily keep track of all the invoices and payments for accounting purposes.  Request is also integrated with legislation across the world to remain compliant with the trade laws of each individual country.  Who Are the Founders of Request? The founders of Request are Christophe Lassuyt and Etienne Tatur.  Christophe Lassuyt is currently the chief financial officer at Request. Before this position, he co-founded MONEYTIS.  Etienne Tatur is the chief technical officer of Request. Prior to this, he also co-founded MONEYTIS and worked as a lead developer at QOBUZ, a music streaming service.  What Makes Request Unique? The payments on Request are performed by simply sending an invoice through the blockchain; the counterparty can then detect the request and pay it with one click in a peer-to-peer manner. The fact that the payments are push-generated instead of pull-generated is one of Request’s key advantages. There is no need for users to share their account information. The use of blockchain technology also eliminates the need for third-party processors, resulting in a reduction in transaction costs.  The Request Network leverages decentralized blockchains such as Ethereum and IPFS for an increased level of security, privacy and data ownership for the end-user. The platform does have transaction fees, which is a cost that is required to broadcast a change to the blockchain network. The transaction fees are used to incentivize miners to reach consensus on the state of the network.  REQ can be stored on wallets such as Metamask, MyEtherWallet, Ledger, imToken, Trezor, Atomic Wallet, Jaxx Liberty and Trust Wallet.  How Many Request (REQ) Coins Are There in Circulation? REQ is an ERC-20 token that can be spent to use the Request Network.  A portion of the REQ fee is burned at a rate that is determined by the current supply and the exchange rate with other currencies.  Request’s (REQ) circulating supply is at 999,912,165 REQ as of February 2021 and the maximum supply is 999,983,984 tokens.  How Is the Request Network Secured? REQ is an ERC-20 token based on the Ethereum platform. The requests made with REQ are stored on an immutable digital ledger. This ledger also serves as proof for all auditing purposes.

Request Network

Request Network is trending as long-term holders debate whether the project's quiet communication and stagnant price action signal a permanent decline or an inevitable comeback akin to its historic spikes. Community sentiment is deeply polarized, with some investors holding out for a repeat of past bull market runs, while others express frustration over dwindling liquidity and a perceived lack of development updates.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently seeing high volatility and active community speculation as traders debate whether its recent price action represents a healthy consolidation or a deeper pullback amid broader market uncertainty. Community discussions are heavily focused on meme coin ecosystem activity, institutional staking participation, and the potential for a breakout if the asset can reclaim key technical resistance levels.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is trending as investors react to increased institutional integration, specifically its expanding role in providing oracle infrastructure for real-world assets and cross-chain messaging. Community sentiment remains mixed, with vocal supporters highlighting fundamental utility and long-term accumulation, while others express frustration over recent price action and broader market volatility.

Daddy Darth Sidious

SIDIOUS is gaining community attention as traders speculate on its potential in a competitive 'Daddy Wars' narrative alongside related tokens like DARTH and MAULCOIN. Participants are actively discussing market rotation strategies, low market cap entry points, and the high-risk, high-reward nature of these nano-cap assets.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as its community emphasizes organic growth and long-term conviction over short-term hype, fostering a dedicated base that remains active despite market fluctuations. Enthusiasts are highlighting the project's resilience and viral marketing efforts as key catalysts for sustained interest as they prepare for further ecosystem expansion.

Tidal Trust II - Defiance Daily Target 2X Long IREN ETF

Defiance Daily Target 2X Long IREN ETF

The Defiance Daily Target 2X Long IREN ETF is experiencing heightened investor activity as the community actively debates its potential for short-term leveraged gains amid shifting Bitcoin sentiment and volatility. Traders are closely monitoring the underlying asset's price action and technical support levels, with many discussing aggressive swing trading strategies and the risks associated with daily decay.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wealth Effects LLC Reduces Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Wealth Effects LLC lessened its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 14.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 143,300 shares of t...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Cross Above 200-Day Moving Average   - Here's Why

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell...

Aberdeen Group plc Sells 234,498 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Aberdeen Group plc cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 45.0% during the 4th quarter, according to its most recent disclosure with the...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm...

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiologys 75th Annual Scientific Session and Expo

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its...

<ul class="summary-bullets"><li>Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of its trial.</li><li>Jones Research attributed WVE’s selloff on Thursday to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%.</li><li>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat, while specifically preserving lean muscle mass.</li></ul> Shares of Arrowhead Pharmaceuticals Inc. (ARWR) fell nearly 2% on Thursday before paring back losses after Wave Life Sciences (WVE) announced mixed data from the early stage portion of its trial evaluating its investigational drug WVE-007 in individuals with obesity.Leerink analyst Mani Foroohar said that they are not surprised to see ARWR stock down as material obesity value is baked in at Arrowhead’s $8.5 billion market cap. The firm has a ‘Market Perform’ rating on Arrowhead shares.Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of the trial, with clinically meaningful reductions in visceral fat and waist circumference, after six months. The investigational drug was well tolerated to date up to 600 mg with no treatment discontinuations, the company said.<a href="https://stocktwits.com/symbol/WVE">WVE shares</a> traded 50% lower at the time of writing. &nbsp;<h2 class="st-heading-2">Why The WVE Selloff?</h2>Jones Research attributed WVE’s selloff to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%. The firm believes that while WVE-007 may not be competitive to GLP-1 category weight loss drugs in the general population, there is still a chance for utility in the elderly or patients with metabolic disease.Jones Research has a ‘Buy’ rating on Wave Life with a $35 price target.Leerink analyst Joseph Schwartz, meanwhile, said that the firm likes the continued improvement in visceral fat reduction at 240 mg after six months, as well as the larger reduction on waist circumference and measurable body weight reduction. The stock's reaction premarket seems to remove all value for WVE-007, which is "very overdone," the firm said. Leerink has an ‘Outperform’ rating on WVE shares.<h2 class="st-heading-2">Arrowhead’s Obesity Pipeline</h2>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat while specifically preserving lean muscle mass.While comparisons between Wave and Arrowhead data are impaired by small numbers of patients, differences in baseline, and other factors, the greater than 50% fall in Wave's stock price "highlights the degree of optimism baked into INHBE expectations" and brings questions related to Arrowhead "back to center stage," Foroohar told investors, as per TheFly.BofA, meanwhile, lowered the firm's price target on Arrowhead to $81 from $84 and kept a ‘Buy’ rating on the shares. The analyst said that Wave’s update appears largely priced in.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ARWR stock improved from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/htz-stock-soars-tsa-delays-airports-spike-in-car-rental-searches/cZ3sTFCRIke">HTZ Stock Soars After TSA Delays At Airports Reportedly Result In Spike In Car Rental Searches</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It?

Leerink analyst Mani Foroohar said that they are not surprised to see Arrowhead Pharmaceuticals’ stock down as material obesity value is baked in at the company’s $8.5 billion market cap.

Equity

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down   - What's Next?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down - Here's What Happened...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6% - Here's What Happened

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 8.6% - Time to Buy...

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 12.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 324,251 shares of the biotechnology comp...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.04	--	--	N/A
Q1 '26	$0.04	$0.22	491.83%	BEAT
Q4 '25	-$0.11	-$0.11	1.40%	BEAT
Q3 '25	-$0.95	-$1.26	-32.32%	MISSED
Q2 '25	-$0.44	$2.75	722.20%	BEAT

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest ARWR News

ARWRArrowhead Pharmaceuticals Inc.